- United States
- /
- Biotech
- /
- NasdaqCM:MLTX
Why Are MoonLake's (MLTX) Trial Setbacks Raising New Questions About Management Credibility and Regulatory Risks?

Reviewed by Sasha Jovanovic
- MoonLake Immunotherapeutics recently announced results from its Phase 3 VELA program for sonelokimab in hidradenitis suppurativa, revealing the VELA-2 trial did not achieve statistical significance in its primary endpoint due to intercurrent events in the placebo arm, while VELA-1 showed some efficacy.
- The announcement has prompted multiple legal investigations into whether prior company statements misrepresented the trial’s design and likelihood of success, further spotlighting regulatory and commercial uncertainty.
- We'll examine how the surprising Phase 3 outcome and emerging legal scrutiny may shift MoonLake's investment narrative moving forward.
Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
What Is MoonLake Immunotherapeutics' Investment Narrative?
For anyone considering an investment in MoonLake Immunotherapeutics, belief in this story has long required confidence in the clinical and commercial prospects of sonelokimab, especially in hidradenitis suppurativa (HS). The recent Phase 3 VELA program results marked a crucial turning point: although the composite analysis for VELA-2 missed the primary endpoint due to an unusually high placebo response, secondary analyses and VELA-1 did show efficacy. However, the severe sell-off, nearly wiping out the share price, shifts the near-term narrative. Legal probes into earlier company statements now amplify the regulatory and reputational risks facing MoonLake, while the commercial timeline for sonelokimab in HS becomes more uncertain. Given MoonLake’s lack of revenue, growing losses, and absence of profitability forecasts, the status and outcome of these clinical milestones are now even more vital as both risks and catalysts have become more acute. While other clinical programs continue, confidence hinges on resolving questions around both effectiveness and disclosure. But ongoing legal scrutiny is just one risk demanding investors’ full attention right now.
According our valuation report, there's an indication that MoonLake Immunotherapeutics' share price might be on the expensive side.Exploring Other Perspectives
Explore another fair value estimate on MoonLake Immunotherapeutics - why the stock might be worth as much as 66% more than the current price!
Build Your Own MoonLake Immunotherapeutics Narrative
Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.
- A great starting point for your MoonLake Immunotherapeutics research is our analysis highlighting 3 important warning signs that could impact your investment decision.
- Our free MoonLake Immunotherapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate MoonLake Immunotherapeutics' overall financial health at a glance.
Ready For A Different Approach?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- Uncover the next big thing with financially sound penny stocks that balance risk and reward.
- These 10 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
- Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqCM:MLTX
MoonLake Immunotherapeutics
A clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.
Excellent balance sheet with low risk.
Market Insights
Community Narratives


